Technology - Dual Inhibition of RNA Polymerase I and III as a Novel Strategy for Targeting Ribosome Biogenesis in Cancer

Dual Inhibition of RNA Polymerase I and III as a Novel Strategy for Targeting Ribosome Biogenesis in Cancer

A specially designed peptide blocks two key enzymes needed for ribosome production in cancer cells, shutting down their protein-making machinery and offering a new, more effective way to treat cancer and prevent drug resistance.

Background:

Ribosome biogenesis is a fundamental cellular process involving the coordinated synthesis of ribosomal RNA (rRNA) and transfer RNA (tRNA), which are essential for protein production. In healthy cells, this process is tightly regulated to match physiological needs. However, in cancer cells, ribosome biogenesis is often dramatically upregulated to support the increased demand for protein synthesis required for rapid cell proliferation. This upregulation is driven by heightened activity of RNA Polymerase I (Pol I), which transcribes rRNA, and RNA Polymerase III (Pol III), which transcribes tRNA. Because of their central role in supporting malignant growth, both Pol I and Pol III have emerged as attractive targets for anti-cancer therapies, particularly in tumors characterized by high rates of protein synthesis. Despite the promise of targeting ribosome biogenesis, current therapeutic approaches are limited by their specificity; most available inhibitors are designed to act on either Pol I or Pol III, but not both. This single-target strategy presents a significant drawback: cancer cells can adapt by compensating with the uninhibited polymerase, thereby maintaining ribosome production and undermining the efficacy of the treatment. Additionally, the redundancy between Pol I and Pol III activity can contribute to the development of drug resistance, as tumor cells exploit alternative pathways to sustain their growth. These limitations highlight a critical need for more comprehensive strategies that can simultaneously disrupt both arms of ribosome biogenesis, thereby closing off compensatory mechanisms and improving therapeutic outcomes.

Technology Overview:

A rationally designed peptide inhibitor has been developed to simultaneously target RNA Polymerase I (Pol I) and RNA Polymerase III (Pol III), two enzymes essential for ribosome biogenesis in cancer cells. This peptide works by disrupting the POLR1D/POLR1C heterodimer, a shared subunit interface crucial for the assembly and function of both polymerase complexes. By interfering with this common component, the peptide effectively suppresses the transcriptional activity of Pol I, which synthesizes ribosomal RNAs, and Pol III, which produces transfer RNAs—both necessary for protein synthesis and rapid cell proliferation. This technology is differentiated by its dual-targeting mechanism, which addresses a significant limitation of current therapies that inhibit either Pol I or Pol III alone. Single-polymerase inhibitors can be circumvented by cancer cells through compensatory upregulation of the uninhibited polymerase, reducing treatment efficacy and fostering drug resistance. By simultaneously shutting down both Pol I and Pol III, this peptide inhibitor provides a more comprehensive blockade of ribosome production, directly attacking a critical vulnerability in cancer cell metabolism. This approach not only promises enhanced therapeutic outcomes and reduced resistance but also opens new avenues for precision oncology, diagnostics, and the development of peptide-based therapeutics for other diseases involving aberrant transcriptional regulation.

Advantages:

•   Simultaneous inhibition of RNA Polymerase I and III enhances suppression of ribosome biogenesis in cancer cells.
•   Reduces cancer proliferation by targeting a shared essential subunit interface (POLR1D/POLR1C) critical for polymerase assembly.
•   Potentially lowers drug resistance by preventing compensatory upregulation of either polymerase.
•   May reduce toxicity compared to single-target therapies through more precise dual inhibition.
•   Applicable as a direct anti-cancer therapeutic and as a diagnostic tool for tumors with high Pol I/III activity.
•   Provides a versatile peptide scaffold adaptable for other protein-protein interaction targets and drug delivery systems.
•   Serves as a research tool for synthetic biology and gene expression modulation.
•   Offers a platform for developing anti-microbial and anti-fungal agents targeting analogous polymerases in pathogens.